Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sharon Townson Sells 3,000 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 3,000 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total value of $57,000.00. Following the transaction, the insider directly owned 67,845 shares in the company, valued at approximately $1,289,055. The trade was a 4.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $18.31 on Friday. The company has a market cap of $1.55 billion, a P/E ratio of -12.37 and a beta of 1.60. The stock has a 50-day moving average of $18.63 and a two-hundred day moving average of $18.48. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. On average, analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on GLUE shares. JPMorgan Chase & Co. raised their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Wells Fargo & Company reduced their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Guggenheim decreased their target price on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.50.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in shares of Monte Rosa Therapeutics by 16.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after buying an additional 776 shares in the last quarter. Royce & Associates LP raised its stake in Monte Rosa Therapeutics by 8.3% in the third quarter. Royce & Associates LP now owns 11,024 shares of the company’s stock valued at $82,000 after buying an additional 848 shares in the last quarter. ProShare Advisors LLC lifted its holdings in Monte Rosa Therapeutics by 11.8% during the 4th quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock worth $178,000 after buying an additional 1,199 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of Monte Rosa Therapeutics by 7.5% during the 4th quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock worth $411,000 after acquiring an additional 1,831 shares in the last quarter. 79.96% of the stock is owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.